Phaseline

Companies › Intensity Therapeutics

Intensity Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
INT230-6
Fixed combination of cisplatin, vinblastine and SHAO; intratumoral injection
–Phase 3Sarcoma,Soft Tissue; Triple-negative Breast CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06263231INT230-6Phase 3Sarcoma,Soft TissueOncologyDec 2027
NCT06358573INT230-6Phase 2Triple-negative Breast CancerOncologyOct 2028

From the company's SEC filings

Cash and short-term investments of $8m on 2026-09-30; operating cash outflow about $9m a year; runway about 11 months at that burn, to Sep 2027; 0 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Angiodynamics Can-Fite BioPharma LeonaBio RenovoRx Aura Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.